xxvth international workshop - · pdf filexxvth international workshop on helicobacter and...

XXVth International Workshop on Helicobacter and related bacteria inchronicdigestiveinflammation and gastric cancer

September13–15,2012 Ljubljana,Slovenia

Euro

pean

Hel

icob

acte

r Stu

dy G

roup

(EH

SG)

FinalProgramme

www.helicobacter.org

XXVth International Workshop on Helicobacter and related bacteria

in chronic digestive inflammation and gastric cancer

Ljubljana, SloveniaSeptember 13 - 15, 2012

FINAL PROGRAMME


2

TABLE OF CONTENTS

Welcoming Address ....................................................................................................................................... 3

Acknowledgements ....................................................................................................................................... 4

List of Exhibitors ............................................................................................................................................ 4

Committees – Organisation ........................................................................................................................... 5

Workshops of the EHSG ............................................................................................................................... 5

Location Map ................................................................................................................................................. 6

Programme at a Glance ................................................................................................................................ 7

Scientific Programme

- Thursday, September 13 ........................................................................................................................ 10

- Friday, September 14 ..............................................................................................................................11

- Saturday, September 15 ......................................................................................................................... 19

Scientific Information, Poster Schedule ....................................................................................................... 24

General Information ..................................................................................................................................... 25

Registration Details ..................................................................................................................................... 28

Networking Events....................................................................................................................................... 28


3

WELCOMING ADDRESS

Dear colleagues and friends,

We would like to cordially welcome you to the XXVth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation in Ljubljana.

The main goal of the EHSG is to offer in its workshop the most comprehensive and distinctly interdisciplinary event on scientific updates on Helicobacter research. We look forward to your valuable contribution and to the exchange of experience and knowledge amongst colleagues from all over the world.

The European Helicobacter Study Group has endeavoured to gather a number of high profile speakers and to increase the interaction between the delegates by continously making small modifications to the schedule.

We do hope that you will enjoy both the scientific and the social side of your stay.

Welcome to Ljubljana!Dobrodošli v Ljubljani

Bojan TepešPresident of the Local Organising Committee

Colm A. O’MorainPresident of the European Helicobacter Study Group

AWARDEES OF THE MARSHALL & WARREN MEDAL

2012 Richard Hunt, Hamilton, ON

2011 Samy Cadranel, Brussels

2010 Reinhold W. Stockbrügger, Maastricht

2009 Pelayo Correa, Nashville, TN

2008 Timo Kosunen, Helsinki

2007 Mike Dixon, Leeds

2006 Barry Marshall, Perth


4

ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:

Main Sponsor

Other Sponsors

INFAI

INFAI GmbHGottfried-Hagen-Str. 60 -62 • D-51105 Cologne, Germany

Phone: ++49 221 880 44-3 • Fax: ++49 221 880 44-55 www.infai.de

INFAI FRANCE SARL85, rue de la Victoire • F-75009 Paris

Phone: ++33 1 42 81 93 19 • Fax: ++33 1 42 81 26 58www.infai.fr

INFAI UK LtdInnovation Centre, University Science Park

University Road, Heslington • YORK YO1 5DG, UK Phone: ++44 1904 435 228 • Fax: ++44 1904 435 229

www.infai.co.uk

Inositolo lo strato slow ne permette l’arrivo in duodeno, migliorandonel’assorbimento. La mesoinosite, o Inositolo, o vitamina B7, presente nei cereali,nelle noci, nei meloni e arance è uno dei rimedi più importanti nei processidi disintossicazione dell’organismo umano; uno zucchero molto sempliceche stimola e attiva i mitocondri facilitando la loro respirazione attivandotutti i processi di “ripulizia” della cellula o dell’organo coinvolto: cuore,cervello, sistema immunitario fegato e muscolo. In studi a doppio cieco èrisultato efficace nel trattamento del disturbo ossessivo-compulsivo. La suaefficacia è equiparabile a quella degli SSRI ed è virtualmente privo di effetticollaterali. Efficace nel trattamento della stipsi, nella ipercolesterolomia enella sindrome dell’ovaio policistico.Antinevritico nella neuropatia diabetica.

grazie all’azione sinergica deisuoi componenti e allatecnologia delle compressedoppio strato Fast/slowconsente un’azione miratadei vari costituentirendendoli efficaci doveservono

Reazioni avverse agli alimenti?

restituisce il sorriso perso

cod 400203 Materiale informativo riservato ai Sigg. Medici

BioActivaL®

Beta-Glucano è un polisaccaride che possiede una forte attivitàantinfiammatoria.A livello intestinale controlla i linfociti Th1 che attivati da patogeni interagisconocon le cellule della mucosa producendo citochine tossiche che a loro voltasostengono i processi infiammatori.Il Beta glucano stimola linfociti Th2 che a loro volta modulano e attenuano ilinfociti Th1 ottenendo in questo modo l’equilibrio tra i due sistemi linfocitari.Con questo meccanismo si ottiene una riduzione dell’infiammazione un aumentodel Ph intestinale e di conseguenza un ambiente sfavorevole per l’attecchimentoe la riproduzione dei patogeni e un ambiente favorevole alla colonizzazione dellaflora probiotica.I linfociti Th2 sono cellule immunitarie, che fungono da attivatori della rispostaimmunitaria, stimolando la proliferazione delle cellule T killer e cellule B, che hannouna specificità antigenica e promuovono una risposta mirata sui microrganismipatogeni e non sui tessuti che li ospitano.Inoltre il betaglucano diminuisce la permeabilità intestinale, contrastandol’entrata in circolo di sostanze particolarmente dannose.

Strato fast

miscela enzimatica amilasi, proteasi, aminoglucosidasi, lipasi, lattasi, cellulasi.La loro presenza all’interno di Biointol ha il significato di contribuire ai processidigestivi in supporto a una carente produzione da parte delle cellule degliorgani normalmente deputati.

Strato slow

Abuso di farmaci (specie antibiotici)Abuso di cibi conservati e additiviInfezioni virali-batteriche e parassitarieStress emotiviAumentata sensibilità soggettivaDiminuita capacità digestiva enzimatica

le reazioni al cibo sono sempre più frequenti

-Bruijnzeel-Koomen C., Ortolani C., Aas K., et al.:"Adverse reaction to food" ( European Academy ofAllergology and Clinical Immunology). Allergy 50,623,1995.

-Perino A.: Allergia e intolleranza alimentare, 2a Edizione, Pacini, Pisa, 2001,p.222.

-Hong, F; Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX,Cheung NK, Ross GD (2004-07-15). "Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activityof antitumor monoclonal antibodies in murine tumor models".Journal of immunology (Baltimore, Md. :1950) †173 (2): 797-806.

-Vetvicka, V; Thornton BP, Ross GD (1996-07-01). "Soluble beta-glucan polysaccharide binding to thelectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates aprimed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells".The Journal of clinical investigation 98 (1): 50-61.

-Kirmaz, C; Bayrak P, Yilmaz O, Yuksel H. (June 2005). "Effects of glucan treatment on the Th1/Th2balance in patients with allergic rhinitis: a double-blind placebo-controlled study.".European cytokine network †16 (2):128-134

-Portera, CA; Love EJ, Memore L, Zhang L, Muller A, Browder W, Williams DL (February 1997). "Effectof macrophage stimulation on collagen biosynthesis in the healing wound".The American surgeon †63 (2): 125-131

-Gerli S., Mignosa M. "Effeti dell'inositolo sulla funzione ovarica e sui fattori metabolici in donne conPCOS; una doppia prova placebo-correlata ripartiti con scelta casuale".Rev.Med. Pharmacol. †2003, 7:151-9

-Fux M, Levine J, Aviv A, Bel )." Inositol treatment of obsessive-compulsive disorder". American Journal of Psychiatry 153 (9): 1219-21.

INGREDIENTI:agenti di carica: CALCIO FOSFATO, CELLULOSAMICROCRISTALLINA, INOSITOLO, MISCELA ENZIMATICADI ORIGINE VEGETALE (contenente: proteasi 3000 HUT,amilasi 1500 DU, amiloglucosidasi 2AG, lipasi 75 FIP, cellulasi300 CU,lattasi 500 ALU e pectinasi 7 ENDO-PG)*.MALTODESTRINA, INULINA,ESTRATTO DI LIEVITO (Saccharomyces cerevisiae)TITOLATO IN BETA-GLUCANI.STEARINA VEGETALE,antiagglomeranti:CARBOSSIMETILCELLULOSA SODICA RETICOLATA,BIOSSIDO DI SILICIO, MAGNESIO STEARATO, agente di rivestimento:GOMMA LACCA.

(*): contenente maltodestrina

Dose giornaliera e modalità d!uso:2 compresse al giorno durante i pastiNon eccedere la dose consigliataConservare in luogo fresco ed asciutto al riparo dalla luce.Tenere fuori dalla portata dei bambini al di sotto dei tre anni.Gli integratori non vanno intesi come sostituto di una dietavariata.

INFORMAZIONE NUTRIZIONALE

Sostanze ad effetto nutritivo o fisiologico Per dose giornaliera (2compresse)

STRATO FAST

STRATO SLOW

Miscela enzimaticaBeta-glucani da estratto di Lievito(Saccharomyces cerevisiae)

Inositolo

250 mg110 mg

300 mg

INDICAZIONIQuando lo stile alimentare necessita di una integrazionedi enzimi, betaglucani e simbiotici.

Bibliografia

LIST OF EXHIBITORS

As per printing date

Aptalis Pharma, Houdan, France

Ewopharma d.o.o., Ljubljana-Crnuce, Slovenia

Infai GmbH, Köln, Germany

Krka d.o.o, Novo Mesto, Slovenia

Lek Pharmaceuticals d.d., Ljubljana, Slovenia

Mevi d.o.o., Maribor, SLOVENIA

Nycomed: A Takeda Company, Ljubljana, Slovenia

Pliva Ljubljana d.o.o., Ljubljana-Crnuce, Slovenia


5

COMMITTEES – ORGANISATION

Local Organizing CommitteePresidentBojan Tepeš (Ljubljana)

MembersMarko Banić (Rijeka)Matjaž Homan (Ljubljana)Alojz Ihan (Ljubljana)Miroslava Katičič (Zagreb)Borut Štabuc (Ljubljana)Milan Stefanovič (Bled)Davor Štimac (Rijeka)Ante Tonkič (Split)

European Helicobacter Study Group (EHSG)PresidentColm A. O’Morain, Ireland

MembersLeif P. Andersen, DenmarkAnthony Axon, United KingdomLars Engstrand, SwedenGiovanni Gasbarrini, ItalyJavier P. Gisbert, Spain Ernst Kuipers, The Netherlands José C. Machado, PortugalPeter Malfertheiner, GermanyFrancis Mégraud, FranceAri P. Ristimäki, FinlandTheodore Rokkas, Greece

Emeritus MembersMichel A.L. Deltenre, BelgiumPierre Michetti, SwitzerlandJosé M. Pajares Garcia, SpainAshley B. Price, United KingdomMario G. Quina, PortugalErik A.J. Rauws, The NetherlandsPentti I. Sipponen, FinlandTorkel M. Wadström, Sweden

Honorary MembersFranco Bazzoli, ItalyJames G. Fox, United States David Y. Graham, United StatesAdrian Lee, AustraliaBarry Marshall, AustraliaGuido N.J. Tytgat, The Netherlands

Corresponding FellowsNiyaz Ahmed, IndiaLuis G. Vaz Coehlo, BrazilToshio Fujioka, JapanHyun Chae Jung, KoreaVarocha Mahachai, ThailandYaron Niv, IsraelShu Dong Xiao, Chin

Organising OfficesCore Agency Vienna Medical AcademyAlser Strasse 4A-1090 Vienna, AustriaPhone: +43 1 405 13 83 0Fax: +43 1 407 82 [email protected]

Technical Exhibition MAWFreyung 6A-1010 Vienna, AustriaPhone: +43 1 536 63 15Fax: +43 1 535 60 [email protected]

Workshops of the EHSG• Bordeaux (1988)• Ulm (1989) • Toledo (1990)• Bologna (1991) • Dublin (1992) • Brussels (1993) • Houston (1994) • Edinburgh (1995)• Copenhagen (1996)

• Lisbon (1997) • Budapest (1998) • Helsinki (1999) • Rome (2000) • Strasbourg (2001) • Athens (2002)• Stockholm (2003)• Vienna (2004)• Copenhagen (2005)

• Wroclaw (2006)• Istanbul (2007)• Riga (2008)• Porto (2009)• Rotterdam (2010)• Dublin (2011)• Ljubljana (2012)• Madrid (2013)

Next Workshop

Madrid, Spain, September 12-14, 2013


6

LOCATION MAP

Gra

nd U

nion

Hal

l

The

Whi

te H

all

Lunc

h(T

he G

lass

Hal

l)

Post

ers

(Gar

den

Hal

l)

Union Garden

RestaurantReg

istr

atio

nC

offe

e - E

xhib

ition

ReceptionGHU Executive

ReceptionGHU

Business

Silver Room

Gra

nd U

nion

Hal

l

Main Entrance, Miklošičeva cesta 1

ReceptionGHU

Business


7

PROGRAMME AT A GLANCE

Thursday, September 13, 2012

18.00 – 19.00 hrs Celebration of 30 years of Helicobacter pyloriThe White Hall

The impact of the discovery of H. pylori on:

Gastroenterology: A. Axon (Leeds, UK)

Pathology: P. Sipponen (Helsinki, Finland)

Bacteriology: F. Mégraud (Bordeaux, France)

20.00 hrs Welcome Reception


8


Friday, September 14, 2012

08.30 – 09.15 hrs Opening ConferencesGrand Union Hall

Tridimentional structure if the CagA oncoprotein, M. Hatakeyama (Tokyo, Japan) Gut microbiome and its modulation by probiotics, J. Versalovic (Houston, TX, USA)

09.15 – 11.00 hrs Symposium: Gastric microbiomeGrand Union Hall

Methods to study the microbiome, C. Belzer (Wageningen, The Netherlands)

Gastric microbiome among Korean Gastric cancer patients, Y.C. Lee (Seoul, Korea)

Gastric microbiota & nitrosamines, K. Sugano (Jichi, Japan)

The gut microbiome of Ötzi, the ice man, L. Engstrand (Stockholm, Sweden)11.00–11.30 hrs Coffee break

11.30–13.00 hrs Parallel Workshops 1 – 2 W1 Microbiology, Molecular Genetics & Virulence

FactorsGrand Union Hall

W2 Epidemiology and PediatricsThe White Hall

13.00–13.30 hrs Lunch

13.30–14.30 hrs Poster RoundsP1 Microbiology, Molecular Genetics & Virulence Factors

P2 Epidemiology, Pediatrics & Diagnosis

P3 Inflammation & Host Response, Immunity 14.30–16.00 hrs Symposium: Management of patients at high risk of

gastric cancerGrand Union Hall

Who are the high risk patients? A. Axon (Leeds, UK)

Histological assessment of premalignant conditions, A. Ristimäki (Helsinki, Finland)

Non-invasive screening for gastric cancer in Europe, A. de Vries (Rotterdam, The Netherlands)

Surveillance of patients at risk, M. Asaka (Sapporo, Japan)16.00–16.30 hrs Coffee break

16.30–18.00 hrs Parallel Workshops 3 – 4 W3 Inflammation and Host Response

Grand Union HallW4 Clinical Trials and Drug Resistance

The White Hall

20.00 hrs EHSG Conference Dinner(Ticket required)


9


Saturday, September 15, 2012

08.30–10.00 hrs Symposium: Dynamics of chronic infectionsGrand Union Hall

H. pylori infection and associated diseases along the centuries, A. Sonnenberg (Portland, OR, USA)

Dynamics of other chronic bacterial infections, D. Graham (Houston, TX, USA)

Changing patterns of H. pylori associated diseases in Asia, V. Mahachai (Bangkok, Thailand)

Dynamics of H. pylori infection in a given patient, N. Ahmed (Hyderabad, India)10.00–10.30 hrs Coffee break

10.30–12.00 hrs Parallel Workshops 5 – 6 W5 Gastric Cancer and preneoplastic lesions

Grand Union HallW6 Extra-Digestive Diseases and Other Helicobacters

The White Hall12.00–12.30 hrs Lunch

12.30–13.30 hrs Poster Rounds P4 Clinical Trials and Drug Resistance

P5 Gastric Cancer and preneoplastic lesions

P6 Extra-Digestive Diseases and Other Helicobacters, NSAIDs & Novelties13.30–15.00 hrs Symposium: H. pylori infection and areas of

uncertainties & controversiesGrand Union Hall

H. pylori & the oesophagus, P. Malfertheiner (Magdeburg, Germany)

H. pylori & the colon, T. Rokkas (Athens, Greece)

H. pylori & metabolic syndrome, F. Franceschi (Roma, Italy)

H. pylori & the brain, L. Letenneur (Bordeaux, France)15.00–15.30 hrs Aptalis Pharma Special Lecture

Grand Union HallManagement of H. pylori treatment failures, J. Gisbert (Madrid, Spain)

15.30–16.00 hrs Coffee break

16.00–17.00 hrs Debate: Functional dyspepsia. What comes first: PPI or H. pylori eradication?

Grand Union HallPPI: J.H. Wandall (Mogeltonder,Denmark)

H. pylori eradication: P. Moayyedi (Hamilton, ON, Canada)17.00–18.00 hrs Closing conferences

Grand Union Hall

Epigenetic changes in gastric cancer, G. Nardone (Napoli, Italy)

Critical views on the potential benefits of H. pylori infection, J. Atherton (Nottingham, UK)

Awarding of the Marshall & Warren Medal to Richard Hunt, Hamilton, ON, Canada18.00–18.15 hrs Presentation of the next meeting Madrid Spain

Closing remarksGrand Union Hall


10

PROGRAMME THuRSDAy, SEPTEMbER 13

18.00 - 19.00 hrs Celebration of 30 years of Helicobacter pyloriRoom: The White Hall

Chair: B. Tepeš (SI) C. O’Morain (IE) M. Asaka (JP)

Speaking Time: 20’

Recent progress in diagnosis and treatment of early gastric cancer and strategy of the impact of the discovery of H. pylori on:

• Gastroenterology: A. Axon (Leeds, UK) • Pathology: P. Sipponen (Helsinki, Finland) • Bacteriology: F. Mégraud (Bordeaux, France)

20.00 hrs Welcome Reception

ThursdayFriday

Saturday


11

PROGRAMME FRIDAy, SEPTEMbER 14

08.30 – 09.15 hrs Opening conferences Room: Grand Union Hall

Chair: B. Tepeš (SI) C. O’Morain (IE)

Speaking Time: 17’+4’

Tridimentional structure if the CagA oncoprotein M. Hatakeyama (Tokyo, Japan) Gut microbiome and its modulation by probiotics J. Versalovic (Houston, TX, USA)

09.15 – 11.00 hrs Symposium: Gastric microbiomeRoom: Grand Union Hall

Chair: P. Malfertheiner (DE) G. Gasbarrini (IT)


Methods to study the microbiome C. Belzer (Wageningen, The Netherlands) Gastric microbiome among Korean Gastric cancer patients Y.C. Lee (Seoul, Korea) Gastric microbiota & nitrosamines K. Sugano (Jichi, Japan) The gut microbiome of Ötzi, the ice man L. Engstrand (Stockholm, Sweden)

11.00 – 11.30 hrs Coffee break

Thur

sday

Frid

aySa

turd

ay


12


11.30 – 13.00 hrs Workshop 1. Microbiology, Molecular Genetics & Virulence Factors Room: Grand Union Hall

Chair: S. Jeverica (SI) J. Versalovic (US) Speaking time: 12’+3’

W1.1 Prevalence and clinical significance of homA and homb, two novel Helicobacter pylori virulence markers, in Slovenian paediatric populationA. Šterbenc1, M. Homan2, B. J. Kocjan1, B. Luzar3, N. Zidar3, M. Poljak1; 1Institution of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 2Department of Gastroenterology, Hepatology and Nutrition, University Children‘s Hospital, Ljubljana, Slovenia, 3Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

W1.2 Identification of protein-protein interactions in the TFS4 type IV secretion system of Helicobacter pyloriM. N. Alandiyjany, J. I. Grove, R. M. Delahay; Centre for Biomolecular Sciences and Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom.

W1.3 Screening of prophage sequences among Helicobacter pylori isolatesA. Timóteo1,2, S. Breurec3, M. Oleastro4, M. Roxo-Rosa4,5, J. M. B. Vítor6, P. Lehours7, F. F. Vale1; 1Faculdade de Engenharia - Universidade Católica Portuguesa, Sintra, Portugal, 2Faculdade de Ciências - Universidade de Lisboa, Lisboa, Portugal, 3Pasteur Institut Dakar Sénégal, Dakar, Senegal, 4Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa, Portugal, 5BioFIG, Lisboa, Portugal, 6iMed. Faculdade de Farmácia - Universidade de Lisboa, Lisboa, Portugal, 7INSERM U853, Bordeaux, France.

W1.4 Gene polymorphisms of microRNAs in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancerJ. Kupcinskas1, T. Wex2, R. Steponaitiene1, S. Juzenas1, M. Leja3, G. Kiudelis1, L. Jonaitis1, J. Skieceviciene1, P. Malfertheiner2; 1Lithuanian University of Health Sciences, Kaunas, Lithuania, 2Clinic of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany, 3Faculty of Medicine, University of Latvia, Digestive Diseases Center, Riga, Latvia.

W1.5 Variation in Helicobacter pylori cagA promoter region is associated with CagA expressionR. M. Ferreira1,2, J. C. Machado1,2, C. Figueiredo1,2; 1IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 2Faculty of Medicine of the University of Porto, Porto, Portugal.

W1.6 Functional characterisation of a VirD2-like relaxase component of a novel Type IV secretion system in Helicobacter pyloriJ. I. Grove, R. M. Delahay; Centre for Biomolecular Sciences and Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom.

13.00 – 13.30 hrs Lunch

ThursdayFriday

Saturday


13


11.30 – 13.00 hrs Workshop 2. Epidemiology and Pediatrics Room: The White Hall

Chair: M. Homan (SI) L.V. Coelho (BR) Speaking time: 12’+3’

W2.1 Incidence of Helicobacter pylori infection in children during a one-year follow-up and the infection status in families in a rural area of Japan.M. Okuda1, S. Kikuchi2, J. Ueda2, T. Osaki3, K. Yagyu2, Y. Lin2, K. Maekawa1, H. Yonezawa3, S. Kamiya3, Y. Fukuda1; 1Department of General Medicine and Community Health Science, Hyogo Medical College of Medicine, Sasayama, Japan, 2Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Japan, 3Department of Infectious Diseases, Kyorin University School of Medicine, Mitaka, Japan.

W2.2 A population-based endoscopic survey of Helicobacter pylori infection in MyanmarV. Mahachai1, T. Myint2, T. Swe3, T. May3, T. Uchida4, T. Fujioka5, Y. Yamaoka6, R. Vilaichone7; 1Division of Gastroenterology, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand, 2Department of Medicine, Yangon General Hospital,, Yangon, Myanmar, 3Novel Square Medical Clinic, Yangon, Myanmar, 4Department of Molecular Pathology, Oita University, Oita, Japan, 5Department of Gastroenterology, Oita University, Oita, Japan, 6Department of Medicine-Gastroenterology, Baylor College of Medicine, Houston, TX, United States, 7Gastroenterology Unit, Department of Medicine, Thammasat University Hospital, Pathumthani, Thailand.

W2.3 Nationwide mortality in duodenal and gastric ulcers; a 40-year follow-up.T. U. Kosunen1, E. Pukkala2, H. Rautelin1,3; 1University of Helsinki, Helsinki, Finland, 2Finnish Cancer Registry, Helsinki, Finland, 3University of Uppsala, Uppsala, Sweden.

W2.4 Pre-neoplastic lesions in gastric biopsies of children are not dependent on infection with cagA, vacA, iceA and babA2 strainsM. Homan1, B. J. Kocjan2, A. Šterbenc2, B. Luzar3, N. Zidar3, R. Orel1, M. Poljak2; 1University Children’s Hospital, Ljubljana, Slovenia, 2Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 3Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

W2.5 Dyspepsia and H. pylori infection: a 15 years study.N. Dal Bó1, F. Ferrara1, T. Slongo1, S. Loperfido1, A. Caroli1, R. Marcello1, H. Heras Salvat1, A. Schiavinato1, C. Scarpignato2, F. Di Mario1; 1Department of Internal Medicine, Gastroenterology Unit, Treviso General Hospital, Treviso, Italy, 2Department of Clinical Sciences, Laboratory of Clinical Pharmacology, University of Parma, Parma, Italy.

W2.6 Novel immuno-line system to detect infections with pathogenic H. pyloriG. Goettner1, L. Formicella2, L. Romberg2, C. Bolz2, C. Nölting1, E. Soutschek1, M. Gerhard2; 1Mikrogen GmbH, Neuried, Germany, 2Institute for Microbiology, Immunology and Hygiene, Technical University, Munich, Germany.

13.00 – 13.30 hrs Lunch

Thur

sday

Frid

aySa

turd

ay


14


13.30 – 14.30 hrs Poster Rounds Room: The Garden Hall

The following posters will be discussed with the authors

Poster Round 1: Microbiology, Molecular Genetics & Virulence FactorsChair: P1.01 - P1.15: L. Engstrand (SE)

N. Ahmed (IN)

P1.16 - P1.28: S. Jeverica (SI) J. Versalovic (US)

Poster Round 2: Epidemiology, Pediatrics & DiagnosisChair: P2.01 - P2.15: P. Moayyedi (CA)

A. Sonnenberg

P2.16 - P2.30: M. Homan (SI) L.V. Coelho (BZ)

P2.31 - P2.46: F. Franceschi (IT) V. Machachai (TH)

Poster Round 3: Inflammation and Host ResponseP3.1 - P3.8: A. Ihan (SI)

L.P. Andersen (DK)

ThursdayFriday

Saturday


15


14.30 – 16.00 hrs Symposium: Management of patients at high risk of gastric cancerRoom: Grand Union Hall

Chair: Y.C. Lee (KR) B. Štabuc (SI)


Who are the high risk patients? A. Axon (Leeds, UK) Histological assessment of premalignant conditions A. Ristimaki (Helsinki, Finland) Non-invasive screening for gastric cancer in Europe E. Kuipers (Rotterdam, The Netherlands) Surveillance of patients at risk M. Asaka (Sapporo, Japan)


Thur

sday

Frid

aySa

turd

ay


16


16.30 – 18.00 hrs Workshop 3. Inflammation and Host ResponseRoom: Grand Union Hall

Chair: A. Ihan (SI) L.P. Andersen (DK)


W3.1 IL-8 response of dendritic cells to Helicobacter pylori is determined by strain specific LPSA. N. Kopitar1, M. Skvarc1, J. Kos2, B. Tepeš3, A. Ihan1; 1University of Ljubljana, Medical Faculty Ljubljana, Institute of Microbiology and Immunology, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Pharmacy, Department of Pharmaceutical Biology, Ljubljana, Slovenia, 3Abakus Medico Health Centre Rogaska, Rogaska Slatina, Slovenia.

W3.2 Involvement and source of b-cells activating factor(s) in H. pylori-associated diseasesM. de Bernard1,2, F. Munari2, M. Fassan1, M. A. Cassatella3; 1University of Padova, Padova, Italy, 2Venetian Institute of Molecular Medicine, Padova, Italy, 3University of Verona, Verona, Italy.

W3.3 Mucin expression in Helicobacter pylori associated gastric ulcer diseaseY. Niv1, S. Ho2; 1Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel, 2UCSD, VA Medical Center, San Diego, CA, United States.

W3.4 Myeloid differentiation primary response gene 88 (MyD88) signaling is protective during Helicobacter-induced gastric cancerK. S. Doran1, E. M. Carmona1, A. Banerjee1, M. Obonyo2; 1San Diego State University, San Diego, CA, United States, 2University of California, San Diego, La Jolla, CA, United States.

W3.5 The Hypoxia Induced Factor 1 is Involved in Helicobacter pylori-Induced Pro-Inflammatory Response of Gastric Epithelial Cells in VitroC. Varon1, K. Rouault2, L. Chambonnier1, M. Sineux1, M. Gourmelin1, M. Coutheinx1, F. Mazurier2; 1INSERM U853, Bordeaux, France, 2INSERM U1035, Université Bordeaux Segalen, Bordeaux, France.

W3.6 The effect of H. pylori density on gastric stem cells and gastric mesenchymal stem cellsM. Ugras1, M. Tosun2, F. Aktepe3; 1Yeditepe University Medical Faculty Department of Pediatrics, Istanbul, Turkey, 2Afyon Kocatepe Univ Medical Faculty, Department Histology and Embriology, Afyonkarahisar, Turkey, 3Afyon Kocatepe Univ Medical Faculty, Department of Pathology, Afyonkarahisar, Turkey.

20.00 hrs EHSG Conference Dinner in the Grand Union Hotel (Ticket required)Thursday

FridaySaturday


17


16.30 – 18.00 hrs Workshop 4. Clinical Trials and Drug ResistanceRoom: The White Hall

Chair: T. Filipec Kanizaj (HR) Y. Niv (IL)


W4.1 Tripletherapy guided by molecular detection of antibiotic resistances versus standard tripletherapy for Helicobacter pylori infection: a randomised trialJ. Delchier1, S. Bastuji-Garin1, L. Deforges1, X. Dray2, V. Ozenne2, L. Raskine2, F. Mion3, C. Roure-Sobas3, F. Zerbib4, F. Mégraud5, T. Barrioz6, A. Chryssostalis7, J. Raymond7, G. Buzaglo8, M. Nicolas-Chanoine8, S. Elia9, I. Podglajen9, S. Doumet10, J. Breuil10, S. Nahon11, A. Mangeol11, F. Grattard12, E. Cambau13, C. Burucoa6; 1Hôpital Henri Mondor, Créteil, France, 2Hôpital Lariboisière, Paris, France, 3CHU Lyon, Lyon, France, 4CHU Bordeaux, Bordeaux, France, 5CHU Lyon, Bordeaux, France, 6CHU poitiers, Poitiers, France, 7Hôpital Cochin, Paris, France, 8Hôpital Beaujon, Clichy, France, 9Hôpital EGP, Paris, France, 10Hôpital Villeneuve Saint Georges, Villeneuve Saint Georges, France, 11Hôpital Montfermeil, Montfermeil, France, 12CHU Saint Etienne, Saint Etienne, France, 13Hôpital Saint Louis, Paris, France.

W4.2 Phase IV, prospective, randomized and comparative study between sequential and concomitant therapy for Helicobacter pylori eradication in routine clinical practice. Preliminary results.A. G. McNicholl1,2, A. C. Marín1,2, J. Molina-Infante3, M. Castro4,2, J. Barrio5, J. Ducons6,2, X. Calvet7,2, C. De la Coba8, M. Montoro9, F. Bory10, Á. Perez-Aisa11, M. Forné12,2, M. Ramas-Lopez1,2, I. Moreno-Arza1,13, R. Millan4,2, P. Aranguren6,2, P. Garcia-Iglesia7,2, B. Belloc9, X. Bessa10, E. Sainz12,2, E. Lamas4, A. Figuerola7,2, C. Alvarez10, F. Abad-Santos1,2,13, J. P. Gisbert1,2; 1La Princesa University Hospital, Madrid, Spain, 2CIBERehd, Barcelona, Spain, 3Hospital San Pedro de Alcántara, Cáceres, Spain, 4Hospital Ntra. Sra. Virgen de Valme, Sevilla, Spain, 5Hospital Universitario Río Hortega, Valladolid, Spain, 6Hospital Clínico Universitario ‘Lozano Blesa’, Zaragoza, Spain, 7Hospital de Sabadell, Sabadell, Spain, 8Hospital de Cabueñes, Gijon, Spain, 9Hospital de San Jorge, Huesca, Spain, 10Hospital del Mar, Barcelona, Spain, 11Hospital Costa del Sol, Malaga, Spain, 12Hospital Mutua de Terrassa, Terrassa, Spain, 13CAIBER, Madrid, Spain.

W4.3 Sequential and Quadruple Therapies for Helicobacter pylori Eradication Compared with Triple Therapy in Slovenia: A Multicenter,Prospective, Randomized, Controlled TrialB. Tepes1, M. Vujasinovic2, M. Seruga3, M. Stefanovic4, S. Jeverica5; 1AM DC Rogaska, Rogaska Slatina, Slovenia, 2Bolnica Slovenj Gradec, Slovenj Gradec, Slovenia, 3Bolnica Murska Soboata, Murska Sobota, Slovenia, 4DC Bled, Bled, Slovenia, 5Institute of Microbiology and Immunology MF Ljubljana, Ljubljana, Slovenia.

W4.4 Comparison of three third-line rescue triple regimens for Helicobacter pylori infection in JapanT. Furuta, M. Sugimoto, C. Kodaira, M. Nishino, M. Yamade, T. Uotani, S. Sahara, H. Ichikawa, T. Yamada, S. Osawa, K. Sugimoto, H. Watanabe, K. Umemura; Hamamatsu University School of Medicine, Hamamatsu, Japan.

W4.5 Antimicrobial resistance of Helicobacter pylori isolates in Alaska Native persons from 2000-2011: results from the Alaska Sentinel Surveillance ProjectM. Bruce1, J. Morris1, D. Bruden1, A. Reasonover1, D. Hurlburt1, B. McMahon2; 1CDC, Anchorage, AK, United States, 2Alaska Native Tribal Health Consortium, Anchorage, AK, United States.

W4.6 Time trends in the choice of H.pylori rescue treatments after one or two failures of standard PPI-clarithromycin/metronidazole containing therapy in Referral Centre for H.pylori in Zagreb, CroatiaM. Katicic1, T. Filipec Kanizaj1, A. Mrzljak1, M. Prskalo1, B. Skurla1, T. Borcic1, T. Bradic1, N. Sobocan1, V. Maricic2, S. Naumovski Mihalic1, V. Colic Cvrlje1; 1University Hospital Merkur, Zagreb, Croatia, 2Pliva, Pharmaceutical Industry, Zagreb, Croatia.

20.00 hrs EHSG Conference Dinner in the Grand Union Hotel (Ticket required)

Thur

sday

Frid

aySa

turd

ay


18

NOTES


19

PROGRAMME SATuRDAy, SEPTEMbER 15

08.30 – 10.00 hrs Symposium: Dynamics of chronic infectionsRoom: Grand Union Hall

Chair: M. Banić (HR) K. Sugano (JP)


H. pylori infection and associated diseases along the centuries A. Sonnenberg (Portland, OR, USA) Dynamics of other chronic bacterial infections D. Graham (Houston, TX, USA) Changing patterns of H. pylori associated diseases in Asia V. Mahachai (Bangkok, Thailand) Dynamics of H. pylori infection in a given patient N. Ahmed (Hyderabad, India)

10.00 – 10.30 hrs Coffee Break

Thur

sday

Frid

aySa

turd

ay


20


10.30 – 12.00 hrs Workshop 5. Gastric Cancer and preneoplastic lesions Room: Grand Union Hall

Chair: M. Leja (LV) B. Štabuc (SI) Speaking Time: 12’+3’

W5.1 The angulus biopsy is critical in the histological assessment of premalignant gastric conditions in the stomachM. Varbanova, T. Wex, D. Kuester, P. Malfertheiner; Department for Gastroenterology, Hepatology and Infectious Diseases, Magdeburg, Germany.

W5.2 The gene expression of the Wnt-modulator RACGAP1 is downregulated in H. pylori positive patients with gastric cancer.J. Bornschein1, J. Nielitz1, M. Selgrad1, I. Drozdov2, D. Kuester3, T. Wex1, P. Malfertheiner1; 1Department of Gastroenterology, Hepatology and Infectious Diseases, Magdeburg, Germany, 2King’s College London, BHF Centre of Excellence, Cardiovascular Division, London, United Kingdom, 3Department of Pathology, Magdeburg, Germany.

W5.3 Attenuated Helicobacter pylori-associated gastric cancer in Fat-1 transgenic mice producing ω-3 PuFAK. Hahm1, E. Kim1, H. Hong1, Y. Han1, T. Park1, J. Kang2; 1Gachon University of Medicine, Incheon, Korea, Republic of, 2Harvard Medical School, Boston, MA, United States.

W5.4 Effect of eradication of Helicobacter pylori on recurrence after endoscopic mucosal resection of gastric adenoma and early gastric cancerS. Bae, H. Jung, J. Kang, Y. Park, S. Baek, D. Kim, J. Ahn, M. Kim, K. Choi, K. Choi, H. Song, G. Lee, J. Lee, J. Kim; University of Ulsan, Asan Medical Center, Seoul, Korea, Republic of.

W5.5 Validaton of gastritis OLGA-staging system for gastric cancer risk in a region of high prevalence: a case-control studyI. Choi, S. Cho, M. Kook, C. Kim, J. Lee, B. Nam; Ntional Cancer Center, Goyang, Korea, Republic of.

W5.6 Only minority of gastric adenocarcinomas present with decreased pepsinogen levelsM. Leja1,2,3, G. Ancans1,2, I. Lasina1, I. Liepniece-Karele1,2, D. Rudzite1,2, A. Sivins1,2, R. Skapars1,2, K. Purmalis1, J. Eglitis1,2, I. Daugule1; 1University of Latvia, Riga, Latvia, 2Riga East University hospital, Riga, Latvia, 3Digestive Diseases Centre GASTRO, Riga, Latvia.

12.00 – 12.30 hrs LunchThursday

FridaySaturday


21


10.30 – 12.00 hrs Workshop 6. Extra-Digestive Diseases and Other HelicobactersRoom: The White Hall

Chair: A. Axon (UK) F. Franceschi (IT)

Speaking time: 12’+3’

W6.1 A lentivirus based strategy for expressing the cytolethal distending toxin b subunit of Helicobacter pullorum - a promising alternative to study the effects of this particular genotoxinI. Mocan1,2, C. Varon1,2, B. Mihi1,2, C. Péré1,2, F. Mégraud1,2, D. Laharie1,2, A. Ménard1,2; 1INSERM U853, Bordeaux, France, 2Laboratoire de Bactériologie, Université Bordeaux Segalen, Bordeaux, France.

W6.2 Antibodies anti-CagA cross react with trophoblast cells: a risk factor for pre-eclampsia?F. Franceschi1, N. Di Simone2, D. Roccarina1, A. Tortora1, S. D’Ippolito2, R. Castellani2, F. Di Nicuolo2, G. Gasbarrini3, Y. Yamaoka4, T. Todros5, G. Scambia2, A. Gasbarrini1; 1Internal Medicine, Catholic University, Rome, Italy, 2Gynecology and Obstetrics, Catholic University, Rome, Italy, 3Fondazione Ricerca in Medicina, Bologna, Italy, 4Medicine-Gastroenterology, Baylor College of Medicine and Michael E. DeBakey VAMC, Houston, TX, United States, 5Gynecology and Obstetrics, University of Turin, Turin, Italy.

W6.3 Colonization capacity of Helicobacter heilmannii sensu stricto strains in a Mongolian gerbil modelM. H. Joosten, A. Smet, F. Pasmans, R. Ducatelle, F. Haesebrouck; Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

W6.4 Could gastric Helicobacters other than H. pylori be of significance in idiopathic parkinsonism?S. M. Dobbs1,2,3, A. Smet4, B. Flahou4, R. Dobbs1,2,3, A. Savio5, A. Charlett6, C. Weller2, A. J. Lawson7, D. Taylor2,3, I. Bjarnason1, F. Pasmans4, R. Ducatelle4, F. Haesebrouck4; 1Department of Gastroenterology, King’s College Hospital, London, United Kingdom, 2Pharmaceutical Science, King’s College London, United Kingdom, 3The Maudsley Hospital, London, United Kingdom, 4Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 5Reparto di Anatomia Patologica, Fondazione Poliambulanza Istituto Ospedaliero, Brescia,, Italy, 6Statistics Unit, Centre for Infections, Health Protection Agency, London, United Kingdom, 7Laboratory of Gastrointestinal Pathogens, Centre for Infections, Health Protection Agency, London, United Kingdom.

W6.5 Helicobacter pullorum - A potential gastrointestinal pathogen?A. Sirianni1, N. O. Kaakoush1, M. Raftery2, H. M. Mitchell1; 1School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia, 2Bioanalytical Mass Spectrometry, University of New South Wales, Sydney, Australia.

W6.6 Genomics and microevolution dynamics of human-derived Helicobacter bizzozeroniiT. Schott, P. K. Kondadi, M. Hänninen, M. Rossi; Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.

12.00 – 12.30 hrs Lunch

Thur

sday

Frid

aySa

turd

ay


22


12.30 – 13.30 hrs Poster Rounds Room: The Garden Hall

The following posters will be discussed with the authors

Poster Round 4: Clinical Trials and Drug ResistanceChair:P4.01 - P4.16: D.Y. Graham (US)

C. Belzer (NL)

P4.17 - P4.33: M. Leja (LV) F. Bazzoli (IT)

P4.34 - P4.49: T. Filipec Kanizaj (HR) Y. Niv (IL)

Poster Round 5: Gastric Cancer and preneoplastic lesionsChair:P5.01 - P5.12: A. Ristimäki (FI)

J.C. Machado (PT)

P5.13 - P5.25 G. Nardone (IT) B. Štabuc (SI)

Poster Round 6: Extra-Digestive Diseases and Other HelicobactersChair:P6.01 - P6.09: A. Gasbarrini (IT)

F. Mégraud (FR)

P6.10 - P6.18 A. Axon (UK) F. Franceschi (IT)

13.30 – 15.00 hrs Symposium: H. pylori infection and areas of uncertainties & controversiesRoom: Grand Union Hall

Chair: J. Atherton (UK) D. Štimac (HR)


H. pylori & the oesophagus P. Malfertheiner (Magdeburg, Germany) H. pylori & the colon T. Rokkas (Athens, Greece) H. pylori & metabolic syndrome F. Franceschi (Roma, Italy) H. pylori & the brain L. Letenneur (Bordeaux, France)

ThursdayFriday

Saturday


23


15.00 – 15.30 hrs Aptalis Pharma Special LectureRoom: Grand Union Hall

Chair: T. Rokkas (GR) A. Tonkič (HR)

Management of Helicobacter pylori treatment failure J. Gisbert (Madrid, Spain)


16.00 – 17.00 hrs Debate: Functional dyspepsia. What comes first: PPI or H. pylori eradication? Room: Grand Union Hall

Chair: R. Hunt (CA) M. Katičič (HR)


PPI: J.H. Wandall, (Mogeltonder, Denmark)

H. pylori: Paul Moayyedi (Hamilton, ON, Canada)

17.00 – 18.00 hrs Closing Conferences Room: Grand Union Hall

Chair: J. Gisbert (ES) M. Stefanovič (US)


Epigenetic changes in gastric cancer G. Nardone (Napoli, Italy) Critical views on the potential benefits of H. pylori infection J. Atherton (Nottingham, UK)

Awarding of the Marshall & Warren Medal to Richard Hunt, Hamilton, ON, Canada

18.00 – 18.15 hrs Presentation of the next meeting in Madrid (J. Gisbert) Closing remarksRoom: Grand Union Hall

Chair: C. O’Morain (IE) F. Mégraud (FR)

Thur

sday

Frid

aySa

turd

ay


24

SCIENTIFIC INFORMATION, POSTER SCHEDULE

Oral PresentationsSpeaking TimeThe chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion. Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical SettingAll rooms are equipped with a (Windows) PC and data projector for Power Point presentation only.

Handing in your Presentation:It must then be handed over to the technician in a break at least 1 hour before your talk either via USB-Memory Stick or CD-Rom (30 minutes for talks in the first morning sessions).

Presentation Format - Technical Issues:The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Please bring a CD-ROM, or floppy disk, formatted for Windows® (PC). You may want to carry a second disk or a USB-memory stick as a back-up in case there is any technical problem.File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows XP®). Maximum Resolution: XGA (1024 x 768 pixel)

Poster Presentations

ATTENTION: Posters are on display for one day only. Posters need to be taken off by the author at the end of the day. Posters not removed until then will be removed by the staff. Posters will be discarded, and neither kept or sent to the authors. Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of one of the authors is mandatory during the following times:

Friday, September 14, 2012, 13.30 – 14.30 hrsPoster Round 1: Microbiology, Molecular Genetics & Virulence FactorsPoster Round 2: Epidemiology, Pediatrics & DiagnosisPoster Round 3: Inflammation and Host Response

Mounting of the posters in Rounds 1-3 is possible on Friday, September 14, 2012 from 8.00 hrs Removal on Friday, September 14, 2012, from 16.30 hrs.

Saturday, September 15, 2012, 12.30 – 13.30 hrsPoster Round 4: Clinical Trials and Drug ResistancePoster Round 5: Gastric Cancer and preneoplastic lesionsPoster Round 6: Extra-Digestive Diseases and Other Helicobacters

Mounting of the posters in Rounds 4-6 is possible on Saturday, September 15, 2012 from 8.00 hrs Removal on Saturday, September 15, 2012, from 15.30 hrs.

FormatThe usable surface on the poster board is 90 cm width x 150 cm height (portrait format). Adhesive material will be made available.


25

GENERAL INFORMATION

In alphabetical order.

BadgesParticipants should collect name badges from the conference registration desks. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Cancellations and RefundsNotice of cancellation had to be made in writing by email or fax to the Congress Office.The policy for refunding registration fees is as follows:Written cancellation received:- Before August 15, 2012: 75% refund- After August 15, 2012: no refundThe date of the email or fax ID is the basis for considering refunds. Refunds will be made after the congress.

Certificate of AttendanceConfirmations of attendance will be issued at the registration desk.

Cash DispensersATMs are widely available in Ljubljana. Local currency (Euro) can also be obtained from banks and exchange bureaus.

CME Credits The “XXVth International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer” was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Coffee Breaks and LunchDuring the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges.Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Price per day: EUR 14.-. Lunch tickets are not refundable.

Congress VenueGRAND HOTEL UNION, d.d.Miklošičeva cesta 11000 Ljubljana, SLOVENIJAWeb: www.gh-union.siMap: Grand Union Hotel

Currency The official currency of Slovenia is the Euro (EUR).1 EUR = 1,25 USD = 0,79 GBP = 98,64 JPY = 1,20 CHF = 8,34 SEK = 7,45 DKKas per date of printing.

Electricity Supply220V - 50Hz; C & F, plugs type C, E & F (European Standard Schuko). Connectors can be obtained from your hotel reception or electronic stores.

GSM cell phone roamingGSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire beforehand at your provider which roaming company in Slovenia offers the cheapest tarifs.

InternetYou will find Internet cafés throughout the city. WIFI is available, please ask for a ticket with the code at the hotel reception.


26

GENERAL INFORMATION

LanguageThe official language of the congress is English (no simultaneous translation).

LiabilityIn registering for the EHSG 2012 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the registration desk at the Congress Centre Thursday, September 13, 2012: 15.00 – 19.00 hrsFriday, September 14, 2012: 08.00 – 18.00 hrsSaturday, September 15, 2012: 08.00 – 18.15 hrs

Poster RemovalThe organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept or mailed to the author after the meeting.

PresentationsAll presenters should hand in their electronic presentation to the technician in a break at least 1 hour before the start of the session (30 minutes for the talks of the first morning sessions).

Safety - CrimeVisitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern.Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking PolicyThe EHSG 2012 Workshop is a “No-smoking-Conference”.

StaffIf you should have any questions, the congress staff will be pleased to help you.

Travel - How to travel from the Airport to Ljubljana Center BusThere are frequent bus connections to the Slovenian main railway station in Ljubljana. The price is 4,10 EUR. The journey time is approximately 45 minutes. Tickets are purchased on the bus.Please find more information on http://www.lju-airport.si/eng/passanger-visitors/getting-here/bus-and-shuttle

ShuttlesA few companies offer affordable rates when sharing a car with colleagues, starting with 5 EUR/person (6-8 persons). Please see their websites for more information:

www.turanus.comwww.goopti.comwww.mnj.siwww.taxibrnik.co.uk


27

GENERAL INFORMATION

TaxiA taxi rank is right in front of the airport terminal. Taxis are available according to the actual arrivals of flights. A fare from the Airport to Ljubljana City costs approximately 39 EUR (depending on the desired destination of the trip).

The company recommended by Grand Union Hotel:ORBITA d.o.o., Kamniška 49, SI-1217 Vodice, Slovenia tel: +386 40 88 77 66, +386 40 88 77 55 web: http://www.orbita.si, email: [email protected]

Weather in LjubljanaSeptember in Ljubljana• Average temperature: 17ºC / 63ºF• Average high: 22ºC / 72ºF• Average low: 12ºC / 54ºF• Average rainfall: 37 mm / 1.5 in


28

REGISTRATION DETAILS

Registration Fees Payment received before July 15, 2012 After July 15, 2012 and on siteRegular Participants EUR 300.– EUR 400.–Young Scientists (<35 years) EUR 150.– EUR 200.–Students (< 30 years) EUR 100.– EUR 100.–Company Representatives EUR 450.– EUR 550.–Day Ticket - EUR 200.–Networking Evening EUR 50.– EUR 50.–

Payment of Registration fees may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

Please note The reduced registration fee was only applicable, if it has been credited to the congress account before the deadline. Registering before July 15, 2012 without performing an actual payment was not sufficient to benefit from the reduction.

What is covered by the registration fee? • Admission to all scientific sessions and the exhibition• Admission to the networking mixer• Abstract book and programme • 1 copy of “Year in Helicobacter 2012”• Refreshments during coffee breaks

Cancellations Notice of cancellation must have been made in writing by email or fax to the Congress Office. The date of the email/fax ID was the basis for considering refunds. Registration fees may be refunded after the workshop as follows: - Cancellation received before August 15, 2012: 75% refund - after August 15, 2012: no refund

SOCIAL EVENTS

Thursday, September 13, 2012, 20.00 hrsNetworking Mixer at the Ljubljana CastleFree for registered participants, however registration for this event is mandatory.

Friday, September 14, 2012, 20.00 hrsEHSG Networking Evening in the Grand Union Hotel Price: EUR 50.-

Krka – one of the world’s leading generic pharmaceutical companies with its own clinical studies (1)

Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia, www.krka.si

Therapeutic indications, dosage and method of administration Gastroesophageal re�ux disease (GERD) Treatment of erosive re�ux esophagitis (40 mg once daily for 4 to 8 weeks), long-term management of patients with healed esophagitis to prevent relapse (20 mg once daily), symptomatic treatment of GERD (20 mg once daily in patients without esophagitis. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily.). In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori Healing of Helicobacter pylori-associated duodenal ulcer, prevention of relapse of peptic ulcers in patients with Helicobacter pylori-associated ulcers (20 mg Emanera/Emozul with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days). Patients requiring continued NSAID therapy Healing of gastric ulcers associated with NSAID therapy (The usual dose is 20 mg once daily. The treatment duration is 4–8 weeks.). Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk (20 mg once daily). Prolonged treatment after IV-induced prevention of rebleeding of peptic ulcers (40 mg once daily for 4 weeks). Treatment of Zollinger-Ellison syndrome (The recommended initial dosage is 40 mg twice daily. The majority of patients can be controlled on doses between 80 to 160 mg – the dose should be divided and given twice daily.). Children below the age of 12 years Emanera/Emozul should not be used in children younger than 12 years since no data are available. The capsules should be swallowed whole with some water. The capsules should not be chewed or crushed. The capsules can also be opened and the pellets mixed in non-carbonated water. They can be administered through a gastric tube. Contraindications Hypersensitivity to esomeprazole, substituted benzimidazoles or to any of the excipients. Esomeprazole should not be administered with nel�navir. Special warnings and precautions for use In the presence of any alarm symptom (e.g. signi�cant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded. Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance. Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character. Special information about some of the ingredients Emanera/Emozul contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insu�ciency should not take this medicine. Interaction with other medicinal products and other forms of interaction The decreased intragastric acidity during treatment with esomeprazole might increase or decrease the absorption of medicines if their mechanism of absorption is in�uenced by gastric acidity. In common with the use of other inhibitors of acid secretion or antacids, the absorption of ketoconazole and itraconazole can decrease during treatment with esomeprazole. If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; the dose of esomeprazole of 20 mg should not be exceeded. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives. Esomeprazole has been shown to have no clinically relevant e�ects on the pharmacokinetics of amoxicillin or quinidine. Fertility, pregnancy and lactation For esomeprazole, clinical data on exposed pregnancies are insu�cient. Caution should be exercised when prescribing to pregnant women. It is not known whether esomeprazole is excreted in human breast milk. No studies in lactating women have been performed. Therefore, Emanera/Emozul should not be used during breast-feeding. Undesirable e�ects Common undesirable e�ects are headache, abdominal pain, constipation, diarrhea, �atulence, and nausea/vomiting. Uncommon undesirable e�ects are peripheral edema, insomnia, dizziness, paresthesia, somnolence, dry mouth, increased liver enzymes, dermatitis, pruritus, rash and urticaria. Other undesirable e�ects are rare and very rare. Contents of container 14 and 28 gastro-resistant capsules of 20 mg or 40 mg of esomeprazole. Legal category Prescription only medicine. Date of revision of the text July 2011. Marketing authorisation holder Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia. Marketing authorisation number PA1347/006/001-002. Further information is available on request.

Therapeutic indications, dosage and method of administration Adults and adolescents 12 years of age and above Symptomatic gastroesophageal re�ux disease (GERD) (20 mg once daily for 2-4 weeks. If this is not su�cient, symptom relief will normally be achieved within a further 4 weeks.), long-term management and prevention of relapse in re�ux esophagitis (20 mg once daily, increasing to 40 mg once daily if a relapse occurs), re�ux esophagitis (40 mg once daily for 4-8 weeks). Adults Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-in�ammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment (20 mg once daily), in combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori (40 mg twice daily for 7-14 days), treatment of gastric ulcer (40 mg once daily for 4-8 weeks), treatment of duodenal ulcer (40 mg once daily for 2-4 weeks), Zollinger-Ellison syndrome and other pathological hypersecretory conditions (Patients should start their treatment with a daily dose of 80 mg, thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.). Children below the age of 12 years Nolpaza is not recommended for use in children below 12 years of age due to limited data on safety and e�cacy in this age group. Tablets should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with some water. Contraindications Hypersensitivity to the active substance, substituted benzimidazoles or to any of the other excipients. Special warnings and precautions for use In the presence of any alarm symptom (e.g. signi�cant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis, anemia or melena) and when gastric ulcer is suspected or present, malignancy should be excluded. In long-term treatment, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance. Special information about some of the ingredients Nolpaza contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine. Interaction with other medicinal products and other forms of interaction Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may reduce the absorption of drugs with a gastric pH-dependent bioavailability, e.g. some azole antifungals as ketoconazole, itraconazole, posaconazole and other medicines, as for example erlotinib. The co-administration of proton pump inhibitors with atazanavir is not recommended. In patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole. Pantoprazole has been shown to have no clinically relevant interactions with clarithromycin, metronidazole and amoxicillin. Fertility, pregnancy and lactation There are no adequate data from the use of pantoprazole in pregnant women. Nolpaza should not be used during pregnancy unless clearly necessary. Excretion into human milk has been reported. Therefore, a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Nolpaza should be made taking into account the bene�t of breast feeding to the child and the bene�t of Nolpaza therapy to the mother. Undesirable e�ects Common undesirable e�ects are diarrhea and headache. Uncommon undesirable e�ects are sleep disorders, headache, dizziness, nausea/vomiting, abdominal distension and bloating, constipation, dry mouth, abdominal pain, pruritus, asthenia and fatigue. Other undesirable e�ects are rare and very rare. Contents of container 14 and 28 gastro-resistant tablets of 20 mg or 40 mg of esomeprazole. Legal category Prescription only medicine. Date of revision of the text November 2011. Marketing authorisation holder Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia. Marketing authorisation number 5363-I-2337-38/11 and 5363-I-2342-43/11. Further information is available on request.For complete information on the products please refer to the summaries of product characteristics (SmPCs). As prescription information may vary from country to country, please refer to the complete SmPC in your country.

EMANERA®/EMOZUL® esomeprazole NOLPAZA® pantoprazole

1. Krka, d. d., Novo mesto. Annual Report 2011.

esomeprazole

A decisive strike against gastric acid

Choose freedom

Modern. Universal. Di�erent.

Gastro-resistant capsules 20 mg and 40 mg

pantoprazoleGastro-resistant tablets 20 mg and 40 mgPowder for solution for injection 40 mg

Slov

enija

, 573

-201

2, A

G.

573-2012_EMANERA_NOLPAZA_adA4_SI(en).indd 1 25.7.2012 8:25:26

xxvth international workshop - · pdf filexxvth international workshop on helicobacter and...

Documents